Axsome Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 2, 2026, reporting total revenues of $259.7 million for the third quarter.
Key Highlights
- Total revenues of $259,691 thousand for the three months ended September 30, 2026, compared to $170,992 thousand in the same period of 2025, according to the filing.
- Net product sales of $249,951 thousand for Q3 2026, up from $169,784 thousand in Q3 2025, as reported in the consolidated statements of operations.
- Nine-month total revenues of $669,269 thousand for the period ended September 30, 2026, versus $442,497 thousand for the same period in 2025.
- Loss from operations of $11,068 thousand for Q3 2026, narrowed from a loss of $46,109 thousand in Q3 2025.
- Total assets of $826,773 thousand as of September 30, 2026, compared to $689,805 thousand at December 31, 2025.
- Accumulated deficit of $1,434,694 thousand as of September 30, 2026, versus $1,305,961 thousand at December 31, 2025.
- 52,576,839 shares of common stock issued and outstanding as of September 30, 2026.
Axsome Therapeutics Financial Results for the Quarter Ended September 30, 2026
According to the filing, Axsome Therapeutics (NASDAQ:AXSM) reported total revenues of $259,691 thousand for the three months ended September 30, 2026, consisting of net product sales of $249,951 thousand and royalty and milestone revenue of $9,740 thousand. For the nine months ended September 30, 2026, total revenues reached $669,269 thousand, compared to $442,497 thousand for the same period in 2025. The company disclosed that royalty and milestone revenue for the nine-month period was $13,563 thousand, up from $3,396 thousand a year earlier.
The filing reported total operating expenses of $270,759 thousand for Q3 2026, including selling, general and administrative expenses of $203,111 thousand, research and development expenses of $50,617 thousand, and cost of revenue of $17,804 thousand. A gain in fair value of contingent consideration of $2,380 thousand was also recorded in the quarter. The resulting loss from operations for Q3 2026 was $11,068 thousand, compared to a loss from operations of $46,109 thousand in Q3 2025. For the nine-month period, the loss from operations was $124,071 thousand, versus $139,805 thousand in the prior-year period.
On the balance sheet, the company disclosed total assets of $826,773 thousand as of September 30, 2026, with cash and cash equivalents of $313,859 thousand and accounts receivable, net, of $343,114 thousand. Total liabilities stood at $721,339 thousand, including short-term borrowings of $70,000 thousand and a long-term loan payable of $118,069 thousand. Total stockholders' equity was $105,434 thousand at September 30, 2026. The filing noted 52,599,985 shares outstanding as of October 26, 2026. The filing contains forward-looking statements that are the company's own and subject to its cautionary language regarding risks and uncertainties.
What Was Disclosed
Axsome Therapeutics filed its quarterly report covering the period ended September 30, 2026, disclosing financial statements including revenues, operating expenses, balance sheet figures, and share counts for Q3 2026 and year-to-date comparisons.






Please wait processing your request...